loading
Tscan Therapeutics Inc stock is traded at $3.99, with a volume of 46,810. It is down -4.13% in the last 24 hours and down -25.05% over the past month. TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$4.12
Open:
$4.13
24h Volume:
46,810
Relative Volume:
0.21
Market Cap:
$220.95M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-1.3806
EPS:
-2.89
Net Cash Flow:
$-64.50M
1W Performance:
-18.05%
1M Performance:
-25.05%
6M Performance:
-57.44%
1Y Performance:
-5.50%
1-Day Range:
Value
$3.93
$4.1679
1-Week Range:
Value
$3.93
$4.85
52-Week Range:
Value
$3.73
$9.69

Tscan Therapeutics Inc Stock (TCRX) Company Profile

Name
Name
Tscan Therapeutics Inc
Name
Phone
857-399-9500
Name
Address
880 WINTER STREET, WALTHAM
Name
Employee
199
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
TCRX's Discussions on Twitter

Compare TCRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
TCRX 3.95 220.95M 21.05M -89.22M -64.50M -2.89
VRTX 447.17 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.51 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.70 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 250.25 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.14 24.49B 3.30B -501.07M 1.03B 11.54

Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-16-24 Initiated BTIG Research Buy
May-13-24 Initiated Needham Buy
Jun-22-23 Initiated Wedbush Outperform

Tscan Therapeutics Inc Stock (TCRX) Latest News

pulisher
04:19 AM

LMR Partners LLP Trims Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat

04:19 AM
pulisher
Nov 20, 2024

Tscan therapeutics sees $4,113 stock purchase by Lynx1 capital - Investing.com India

Nov 20, 2024
pulisher
Nov 20, 2024

TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc - GuruFocus.com

Nov 19, 2024
pulisher
Nov 19, 2024

TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World

Nov 19, 2024
pulisher
Nov 16, 2024

FY2024 Earnings Estimate for TCRX Issued By Lifesci Capital - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

TScan Therapeutics (NASDAQ:TCRX) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Wedbush Research Analysts Boost Earnings Estimates for TCRX - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

TScan Therapeutics Inc (TCRX) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 14, 2024

Wedbush Has Positive Forecast for TCRX FY2028 Earnings - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts By Investing.com - Investing.com Nigeria

Nov 14, 2024
pulisher
Nov 14, 2024

TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

Needham & Company LLC Reaffirms “Buy” Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

TScan Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 13, 2024
pulisher
Nov 12, 2024

Tscan Therapeutics earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada

Nov 12, 2024
pulisher
Nov 12, 2024

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 12, 2024
pulisher
Nov 07, 2024

New Blood Cancer Treatment Shows Continued Response - Streetwise Reports

Nov 07, 2024
pulisher
Nov 07, 2024

Tscan Therapeutics Inc’s (TCRX) 7.56% Increase Justifies A Second Look - Stocks Register

Nov 07, 2024
pulisher
Nov 06, 2024

TScan Therapeutics' (TCRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet? - Simply Wall St

Nov 06, 2024
pulisher
Nov 06, 2024

TScan Therapeutics' SWOT analysis: innovative therapy stock faces pivotal year - Investing.com Australia

Nov 06, 2024
pulisher
Nov 05, 2024

TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

TScan's Blood Cancer Trial Shows Zero Relapses: Breakthrough Phase 1 Results | TCRX Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

Waltham cancer biotech adds to real estate footprint - The Business Journals

Nov 04, 2024
pulisher
Nov 04, 2024

TScan Therapeutics (NASDAQ:TCRX) Enters Second Amendment for Lease Agreement to Expand Operations at Winter Street FacilityOn October 28, 2024, TScan Therapeutics, Inc. finalized a second amendment to its lease agreement with PPF OFF 828-83 - Defense World

Nov 04, 2024
pulisher
Nov 02, 2024

TScan expands Waltham facility with additional lease - Investing.com India

Nov 02, 2024
pulisher
Nov 01, 2024

TScan expands Waltham facility with additional lease By Investing.com - Investing.com UK

Nov 01, 2024
pulisher
Oct 26, 2024

Head to Head Review: ProKidney (NASDAQ:PROK) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World

Oct 26, 2024
pulisher
Oct 21, 2024

The Manufacturers Life Insurance Company Invests $90,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Oct 21, 2024
pulisher
Oct 18, 2024

Where are the Opportunities in (TCRX) - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 15, 2024

BTIG Initiates Coverage of TScan Therapeutics (TCRX) with Buy Recommendation - MSN

Oct 15, 2024
pulisher
Oct 08, 2024

Bank of Montreal Can Acquires Shares of 120,454 TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Bank of Montreal Can Invests $749,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat

Oct 08, 2024
pulisher
Oct 07, 2024

(TCRX) On The My Stocks Page - Stock Traders Daily

Oct 07, 2024
pulisher
Oct 06, 2024

TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Position Lifted by Marshall Wace LLP - MarketBeat

Oct 06, 2024
pulisher
Oct 05, 2024

American Century Companies Inc. Increases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Oct 05, 2024
pulisher
Oct 04, 2024

TCRXTScan Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 04, 2024
pulisher
Oct 04, 2024

TScan Therapeutics Announces Upcoming Presentations at the - GlobeNewswire

Oct 04, 2024
pulisher
Oct 04, 2024

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - StockTitan

Oct 04, 2024
pulisher
Oct 04, 2024

Reviewing TScan Therapeutics (NASDAQ:TCRX) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World

Oct 04, 2024
pulisher
Oct 01, 2024

Tscan Therapeutics Inc [TCRX] Stock bought by Insider Klencke Barbara for $26450.0 - Knox Daily

Oct 01, 2024
pulisher
Oct 01, 2024

Was there any good news for Tscan Therapeutics Inc (TCRX) stock in the last session? - US Post News

Oct 01, 2024
pulisher
Oct 01, 2024

Market Momentum Report: Tscan Therapeutics Inc (TCRX)’s Negative Close at 4.98 - The Dwinnex

Oct 01, 2024
pulisher
Sep 30, 2024

TScan Therapeutics's SWOT analysis: biotech stock faces pivotal year - Investing.com

Sep 30, 2024
pulisher
Sep 28, 2024

TScan Therapeutics, Inc. (NASDAQ:TCRX) Sees Significant Growth in Short Interest - MarketBeat

Sep 28, 2024
pulisher
Sep 25, 2024

92,832 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Bought by Troluce Capital Advisors LLC - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

TScan Therapeutics, Inc. (NASDAQ:TCRX) Director Barbara Klencke Acquires 5,000 Shares - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

TScan therapeutics director buys $26,450 in company stock By Investing.com - Investing.com South Africa

Sep 24, 2024

Tscan Therapeutics Inc Stock (TCRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):